ELTP — ELITE PHARMACEUTICALS INC /NV/
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1053369 ·
Last close
$0.37
Market Cap
$393.21M
52W High
$0.44
52W Low
$0.33
ADV30
592,726
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 31,589,251 | 12,953,175 | 9,012,943 | 18,593,806 | 126,412,637 | 21,094,904 | 46,098,554 |
| Sep 2025 | 36,321,704 | 14,073,033 | 8,213,746 | 13,702,407 | 117,247,811 | 26,617,346 | 55,662,843 |
| Jun 2025 | 40,211,097 | 27,225,970 | 21,699,707 | -5,884,715 | 111,339,370 | 21,737,797 | 63,656,727 |
| Mar 2025 | 31,996,273 | 17,295,108 | 12,757,085 | 16,997,737 | 96,387,477 | 11,315,385 | 42,872,448 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$18,519,746
Investing CF
$-1,281,720
Financing CF
$-4,417,831
CapEx
$-1,281,720
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-94,292,428
Inventory
$25,099,135
Receivables
$48,529,574
ST Investments
—
EBIT TTM
$55,742,191
Pretax Income TTM
$55,231,748
Interest Exp TTM
$510,443
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$140,118,320
EBITDA
$53,271,232
Free Cash Flow
$-474,370
Enterprise Value
$380,721,504
Total Cash
$21,094,904
Total Debt
$6,056,957
Shares Out
1,076,996,442
Trailing EPS
$0.04
Book Value
$0.07
ROE
74.4%
ROA
29.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 84,043,929 | 21,203,894 | -4,314,659 | 96,387,477 | 42,872,448 | — | 7,455,639 |
| Mar 2024 | 56,625,128 | 10,788,769 | 20,108,631 | 83,653,536 | 26,070,718 | — | -3,235,115 |
| Mar 2023 | 34,155,114 | 3,968,809 | 3,561,846 | 40,896,018 | 11,935,758 | — | 3,338,704 |
| Mar 2022 | 32,262,117 | 5,070,710 | 8,898,245 | 35,148,898 | 9,926,871 | — | 6,508,314 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SGMT | Sagimet Biosciences Inc. | $395.86M | $6.47 | — |
| CYDY | CytoDyn Inc. | $390.10M | $0.28 | — |
| BNTC | Benitec Biopharma Inc. | $389.23M | $11.33 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $406.33M | $6.22 | — |
| MNPR | Monopar Therapeutics | $411.79M | $61.47 | — |
News headlines (Yahoo Finance, 1h cache)
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
2026-06-15 11:00 · Yahoo
Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
2026-06-01 11:00 · Yahoo
Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets
2026-04-02 12:00 · Yahoo
The Zacks Analyst Blog Highlights GE Aerospace, Shell, McKesson, Elite Pharmaceuticals and Geospace Technologies
2026-03-18 14:23 · Yahoo
Top Stock Reports for GE Aerospace, Shell & McKesson
2026-03-17 20:10 · Yahoo
Elite Pharmaceuticals Inc (ELTP) Q3 2026 Earnings Call Highlights: Record Revenue Surge and ...
2026-02-24 01:00 · Yahoo
Elite Pharmaceuticals Stock Dips Post Q3 Earnings Despite Revenue Jump
2026-02-20 15:57 · Yahoo
Elite Pharmaceuticals Q3 Earnings Call Highlights
2026-02-19 05:07 · Yahoo
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information
2026-02-17 21:19 · Yahoo
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026
2026-02-11 21:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.